June 29, 2024Open Access

critique of semaglutide (Wegovy®) for obesity management NICE technology appraisal TA875

HKHassan KahalNorth Bristol NHS Trust CWChris WaltonUniversity of Hull

Key Points

Key points are not available for this paper at this time.

Abstract

Wegovy®, semaglutide 2.4 mg, is a glucagon-like peptide-1 analogue that has been approved by the National Institute for Health and Care Excellence (NICE) for the treatment of adults with obesity in the National Health Service (NHS). In this review, we provide a reflection on NICE TA875 and its implementation in the NHS.

KI fragen

Bookmark

View Full Paper

Cite This Study

Kahal et al. (Sat,) studied this question.

synapsesocial.com/papers/68e629b8b6db6435875bcddc https://doi.org/https://doi.org/10.15277/bjd.2024.439

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity2023 · 1,506 citations
2Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial2022 · 813 citations
3Once-Weekly Semaglutide in Adults with Overweight or Obesity2021 · 4,721 citations
4Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity2021 · 1,293 citations
5Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension2022 · 983 citations

KI fragen

Bookmark

View Full Paper